MONECO Advisors LLC Sells 1,696 Shares of GSK plc (NYSE:GSK)

MONECO Advisors LLC decreased its position in GSK plc (NYSE:GSK) by 13.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,622 shares of the pharmaceutical company’s stock after selling 1,696 shares during the quarter. MONECO Advisors LLC’s holdings in GSK were worth $359,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Sunbelt Securities Inc. grew its stake in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Mesirow Financial Investment Management Inc. grew its stake in shares of GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after acquiring an additional 323 shares during the last quarter. Rehmann Capital Advisory Group grew its stake in shares of GSK by 6.3% in the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after acquiring an additional 332 shares during the last quarter. Investment Partners Asset Management Inc. grew its stake in shares of GSK by 2.3% in the third quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock worth $636,000 after acquiring an additional 344 shares during the last quarter. Finally, Bond & Devick Financial Network Inc. grew its stake in shares of GSK by 5.4% in the third quarter. Bond & Devick Financial Network Inc. now owns 7,830 shares of the pharmaceutical company’s stock worth $320,000 after acquiring an additional 400 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Up 1.1 %

GSK opened at $37.03 on Tuesday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The firm’s fifty day moving average price is $34.67 and its two-hundred day moving average price is $37.32. The company has a market capitalization of $76.74 billion, a P/E ratio of 23.29, a P/E/G ratio of 1.12 and a beta of 0.64.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 annualized dividend and a dividend yield of 4.25%. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is currently 98.74%.

Wall Street Analysts Forecast Growth

GSK has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.